Last reviewed: May 22, 2026
Last updated: May 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
No, GLP-1 agonists do not cause diabetes. These medications actively lower blood sugar by stimulating insulin secretion and improving insulin sensitivity. In fact, GLP-1 agonists are a cornerstone of type 2 diabetes treatment and have been shown to reduce hemoglobin A1c (HbA1c) by 1.5-2.0 percentage points in clinical trials.
The confusion often stems from unfamiliarity with how GLP-1 works and misconceptions about injectable medications. Understanding the mechanism, your baseline health status, and how genetic factors in your GLP-1 receptor pathway may influence response can help you and your provider make informed decisions about whether GLP-1 therapy is appropriate for you.
How GLP-1 Agonists Regulate Blood Sugar—Not Raise It
GLP-1 (glucagon-like peptide 1) is a natural hormone your intestines release after eating. GLP-1 agonists mimic this hormone, binding to GLP-1 receptors in the pancreas and brain. This triggers insulin secretion when blood glucose is elevated, suppresses glucagon (which raises glucose), and slows gastric emptying to reduce blood sugar spikes.
The mechanism is fundamentally glucose-dependent: insulin is released only when blood sugar is high. This reduces hypoglycemia risk compared to some older diabetes medications. Studies show GLP-1 agonists improve cardiovascular outcomes and reduce weight, making them one of the most evidence-supported diabetes therapies available.
Clinical Evidence: GLP-1 Safety Profile & Diabetes Risk
Large randomized controlled trials—LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)—demonstrate GLP-1 agonists do not cause new-onset diabetes or worsen glucose control in non-diabetic individuals. Among people with type 2 diabetes, they consistently lower HbA1c and reduce mortality and cardiovascular events. The concern about causing diabetes is not supported by clinical evidence.
| Clinical Outcome |
GLP-1 Agonist Effect |
| Blood glucose (fasting) |
Typically decreases 10–40 mg/dL |
| HbA1c reduction |
1.5–2.0 percentage points in type 2 diabetes |
| Hypoglycemia risk |
Low when used alone; higher risk with insulin or sulfonylureas |
| Cardiovascular events |
Reduced by 12–26% in major trials (LEADER, SUSTAIN-6) |
| New-onset diabetes risk |
Not increased; may prevent progression to diabetes in prediabetic patients |
Who Should and Shouldn't Use GLP-1 Agonists: Provider Evaluation Framework
Your provider evaluates several factors before recommending GLP-1 therapy: fasting glucose, HbA1c, kidney function (eGFR), gastrointestinal history, personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 (MEN-2), and medication interactions. GLP-1 agonists are appropriate for type 2 diabetes, prediabetes with obesity, and cardiovascular disease risk reduction—not for type 1 diabetes or acute illness.
Contraindications include personal or family history of medullary thyroid carcinoma, MEN-2, severe pancreatitis, or severe kidney disease (eGFR < 15 mL/min/1.73m²). Relative cautions include pregnancy, thyroid nodules, and diabetic retinopathy requiring close monitoring. Your provider will determine suitability based on your complete medical history and labs.
Biomarkers, Genetics, and Personalized GLP-1 Response
Beyond traditional labs (glucose, A1c, lipids), emerging evidence suggests genetic variations in the GLP-1 receptor (GLP1R) and GIPR genes may influence medication response and side-effect tolerance. Individuals with certain variants may experience greater glucose-lowering or more pronounced gastrointestinal effects. These predispositions do not determine outcome but can support a more personalized conversation with your provider.
PlexusDx's Precision Peptide Genetic Test examines variants including GLP1R rs6923761 and GIPR rs1800437, which relate to GLP-1 pathway function. The test may help provide context for why one GLP-1 agonist or dosing strategy might suit you better than another. Results should be interpreted with your qualified healthcare provider as part of a comprehensive evaluation—genetics inform probability, not guarantee.
How PlexusDx Supports a More Personalized Approach
PlexusDx recognizes that genetic variation in GLP-1 receptor pathways can influence how efficiently your body processes GLP-1 agonists. By identifying predispositions in genes like GLP1R and GIPR, the Precision Peptide Genetic Test may help provide context for your individual response profile. This information, combined with your clinical labs and provider assessment, supports a more tailored treatment conversation.
The Precision Peptide Genetic Test reveals your genetic predispositions in peptide signaling pathways, including GLP-1 receptor variants and glucose metabolism genes (e.g., FTO rs9939609). These predispositions do not predict exact medication response or guarantee outcomes—they identify areas where your physiology may diverge from population averages. Your provider can use this data to inform dosing, formulation choice (injection vs. oral), and monitoring strategy.
Understanding your genetic context alongside your clinical history, labs, and symptoms can support a more informed conversation with your provider about whether GLP-1 therapy, and which type, is right for you. PlexusDx compounded GLP-1 options (semaglutide injection, tirzepatide injection, oral formulations, and dual-compound protocols) are available through licensed 503A pharmacies, allowing your provider flexibility in personalizing your treatment plan.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Diet With GLP-1 Medications: What You Can Eat
Can You Eat After Injecting Ozempic? Timing & Nausea